Anticoagulation for New Onset Atrial Fibrillation with Rapid Ventricular Response

Risk Assessment for Anticoagulation

The American College of Cardiology recommends anticoagulation decisions be based on the CHA2DS2-VASc score, which assesses stroke risk factors including congestive heart failure, hypertension, age, diabetes, prior stroke/TIA, vascular disease, and sex 1, 2
For men with a CHA2DS2-VASc score of 2 or greater and women with a score of 3 or greater, anticoagulation is strongly recommended by the American College of Cardiology and the American College of Chest Physicians 2, 3

For AFib of less than 48 hours duration with a CHA2DS2-VASc score of 2 or greater in men and 3 or greater in women, heparin, factor Xa inhibitor, or direct thrombin inhibitor should be administered as soon as possible before cardioversion, as recommended by the American College of Cardiology 2
For AFib of 48 hours or longer, or unknown duration, anticoagulation for at least 3 weeks before cardioversion or a transesophageal echocardiogram (TEE) to rule out left atrial thrombus is recommended by the American College of Cardiology and the American College of Chest Physicians 2, 3

The American College of Cardiology recommends anticoagulation for patients with AFib at increased risk of stroke, with a target INR of 2.0-3.0 for warfarin 1
For patients with AFib and acute coronary syndrome (ACS) at increased risk of thromboembolism, anticoagulation is recommended by the American College of Cardiology unless bleeding risk exceeds expected benefit 1

Urgent direct-current cardioversion is recommended for patients with AFib and RVR who have hemodynamic compromise, ongoing ischemia, or inadequate rate control, as recommended by the American College of Cardiology and the American Heart Association 1, 5
Intravenous beta blockers are recommended to slow rapid ventricular response in patients without heart failure, hemodynamic instability, or bronchospasm, as recommended by the American College of Cardiology 1

After cardioversion for AFib of any duration, the decision about long-term anticoagulation should be based on the thromboembolic risk profile (CHA2DS2-VASc score) and bleeding risk profile, as recommended by the American College of Cardiology 2
The American College of Chest Physicians recommends that the presence or absence of symptoms should not influence the decision-making process regarding anticoagulation 7

The American College of Cardiology and the American College of Chest Physicians recommend not basing anticoagulation decisions solely on the presence of RVR; the CHA2DS2-VASc score should guide therapy 2, 8
The American College of Cardiology and the American College of Chest Physicians recommend not withholding anticoagulation in patients with high stroke risk due to concerns about cardioversion; appropriate anticoagulation should be initiated before cardioversion 2, 3
The American Heart Association recommends not using anticoagulation with the sole intent of obviating the need for rate or rhythm control 5